Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130344) titled 'PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Centre Paul Strauss
Condition:
Metastatic Breast Cancer
HER 2 Low-expressing Breast Cancer
Intervention:
Procedure: TAP CT-scan
Procedure: Bone scintigraphy
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: September 2025
Target Sample Size: 262
Countries of Recruitment:
France
To know more, visit https://cli...